{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:40:17Z","timestamp":1777372817162,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005688","name":"Gottfried und Julia Bangerter-Rhyner-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008485","name":"Schweizerische Akademie der Medizinischen Wissenschaften","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008485","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.radonc.2023.109671","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T11:28:00Z","timestamp":1681298880000},"page":"109671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Repeat stereotactic body radiotherapy for oligometastatic disease"],"prefix":"10.1016","volume":"184","author":[{"given":"Jonas","family":"Willmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma","family":"Adilovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Vlaskou Badra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian M.","family":"Christ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiwand","family":"Ahmadsei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Tanadini-Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mayinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolaus","family":"Andratschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109671_b0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109671_b0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109671_b0015","first-page":"e18","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"LancetOncol"},{"key":"10.1016\/j.radonc.2023.109671_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2022.06.100","article-title":"Imaging-based prevalence of oligometastatic disease: a single-center cross-sectional study","author":"Christ","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109671_b0025","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41467-018-04278-6","article-title":"Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis","volume":"9","author":"Pitroda","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2023.109671_b0030","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1002\/cam4.4332","article-title":"Volumetric burden of metastatic lesions drives outcomes in patients with extracranial oligometastatic disease","volume":"10","author":"Cao","year":"2021","journal-title":"Cancer Medicine"},{"key":"10.1016\/j.radonc.2023.109671_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2022.06.064","article-title":"Distant metastasis velocity as a novel prognostic score for overall survival after disease progression following stereotactic body radiotherapy for oligometastatic disease","author":"Willmann","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109671_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djx015","article-title":"Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial","volume":"109","author":"Ruers","year":"2017","journal-title":"J Nat Cancer Inst"},{"key":"10.1016\/j.radonc.2023.109671_b0045","first-page":"4","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.109671_b0050","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109671_b0055","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.radonc.2023.109671_b0060","first-page":"650","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"J Am Med Association Oncol"},{"key":"10.1016\/j.radonc.2023.109671_b0065","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.109671_b0070","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC","author":"Wang","year":"2022","journal-title":"J Nat Cancer Inst"},{"key":"10.1016\/j.radonc.2023.109671_b0075","doi-asserted-by":"crossref","first-page":"6045","DOI":"10.21037\/apm-20-847","article-title":"A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions","volume":"10","author":"Li","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.radonc.2023.109671_b0080","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","article-title":"Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes","volume":"114","author":"Harrow","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109671_b0085","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109671_b0090","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109671_b0095","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ijrobp.2008.04.073","article-title":"Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses","volume":"73","author":"Milano","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109671_b0100","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3390\/curroncol29030140","article-title":"Repeated multimodality ablative therapies for oligorecurrent pulmonary metastatic disease","volume":"29","author":"Macagno","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.radonc.2023.109671_b0105","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2021.12.018","article-title":"An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer","volume":"167","author":"Sheikh","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109671_b0110","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.09.008","article-title":"Final analysis of Consolidative Use of Radiotherapy to Block (CURB) oligoprogression trial - a randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast cancers","volume":"114","author":"Tsai","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109671_b0115","doi-asserted-by":"crossref","unstructured":"Chmura SJ, Winter KA, Woodward WA, Borges VF, Salama JK, Al-Hallaq HA, et al. NRG-BR002: A phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). Journal of Clinical Oncology 2022;40:1007\u20131007. https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.1007.","DOI":"10.1200\/JCO.2022.40.16_suppl.1007"},{"key":"10.1016\/j.radonc.2023.109671_b0120","first-page":"123","article-title":"Recognition of and treatment recommendations for oligometastatic disease in multidisciplinary tumor boards","volume":"38","author":"Christ","year":"2023","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023002098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023002098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:25:01Z","timestamp":1759123501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023002098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":24,"alternative-id":["S0167814023002098"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109671","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repeat stereotactic body radiotherapy for oligometastatic disease","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109671","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109671"}}